  Estimating $T_2$ relaxation time distributions from multi-echo $T_2$-weighted
MRI ($T_2W$) data can provide valuable biomarkers for assessing inflammation,
demyelination, edema, and cartilage composition in various pathologies,
including neurodegenerative disorders, osteoarthritis, and tumors. Deep neural
network (DNN) based methods have been proposed to address the complex inverse
problem of estimating $T_2$ distributions from MRI data, but they are not yet
robust enough for clinical data with low Signal-to-Noise ratio (SNR) and are
highly sensitive to distribution shifts such as variations in echo-times (TE)
used during acquisition. Consequently, their application is hindered in
clinical practice and large-scale multi-institutional trials with heterogeneous
acquisition protocols. We propose a physically-primed DNN approach, called
$P_2T_2$, that incorporates the signal decay forward model in addition to the
MRI signal into the DNN architecture to improve the accuracy and robustness of
$T_2$ distribution estimation. We evaluated our $P_2T_2$ model in comparison to
both DNN-based methods and classical methods for $T_2$ distribution estimation
using 1D and 2D numerical simulations along with clinical data. Our model
improved the baseline model's accuracy for low SNR levels ($SNR<80$) which are
common in the clinical setting. Further, our model achieved a $\sim$35\%
improvement in robustness against distribution shifts in the acquisition
process compared to previously proposed DNN models. Finally, Our $P_2T_2$ model
produces the most detailed Myelin-Water fraction maps compared to baseline
approaches when applied to real human MRI data. Our $P_2T_2$ model offers a
reliable and precise means of estimating $T_2$ distributions from MRI data and
shows promise for use in large-scale multi-institutional trials with
heterogeneous acquisition protocols.
